Disposition of 1064 shares by Michelle Gilson of Arcellx at 86.2155 subject to Rule 16b-3
| ACLX Stock | USD 90.15 0.08 0.09% |
Slightly above 55% of Arcellx's investor base is interested to short. The analysis of the overall investor sentiment regarding Arcellx suggests that many traders are impartial. Arcellx's investing sentiment can be driven by a variety of factors including economic data, Arcellx's earnings reports, geopolitical events, and overall market trends.
Filed transaction by Arcellx Officer: Chief Financial Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
Arcellx Fundamental Analysis
We analyze Arcellx's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arcellx using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arcellx based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Income
Net Income Comparative Analysis
Arcellx is currently under evaluation in net income category among its peers. Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Arcellx Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Arcellx stock to make a market-neutral strategy. Peer analysis of Arcellx could also be used in its relative valuation, which is a method of valuing Arcellx by comparing valuation metrics with similar companies.
Peers
Arcellx Related Equities
| IMVT | Immunovant | 2.40 | ||||
| PCVX | Vaxcyte | 0.96 | ||||
| VKTX | Viking Therapeutics | 0.44 | ||||
| KYMR | Kymera Therapeutics | 0.25 | ||||
| AKRO | Akero Therapeutics | 0.20 | ||||
| ARWR | Arrowhead Pharmaceuticals | 0.19 | ||||
| PTGX | Protagonist Therapeutics | 0.83 | ||||
| NAMS | NewAmsterdam Pharma | 3.96 | ||||
| CRSP | Crispr Therapeutics | 5.47 | ||||
| ALKS | Alkermes Plc | 7.10 |
Additional Tools for Arcellx Stock Analysis
When running Arcellx's price analysis, check to measure Arcellx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcellx is operating at the current time. Most of Arcellx's value examination focuses on studying past and present price action to predict the probability of Arcellx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcellx's price. Additionally, you may evaluate how the addition of Arcellx to your portfolios can decrease your overall portfolio volatility.